-
Merck is in deep negotiations to acquire cancer drug manufacturer HARPOON Therapeutics for approximately $700 million
Merck is in deep negotiations to acquire cancer drug manufacturer HARPOON Therapeutics for approximately $700 million. -
AstraZeneca acquires a Chinese cancer drug developer with a transaction value of approximately $1.2 billion
AstraZeneca announced on Tuesday local time that a final agreement has been signed on the proposed acquisition of Gracell, which will add GC012F CAR-T cell therapy to AstraZeneca's expanding cell the ... -
The INVITAE Cancer Risk test receives FDA marketing approval
The INVITAE Cancer Risk test receives FDA marketing approval.